GBM Immunotherapy (with SandboxAQ)
Glioblastoma (GBM)
Pre-clinicalActive
Key Facts
About iOncologi
iOncologi is a private, pre-revenue biotech founded in 2018, advancing a novel class of RNA therapeutics designed to overcome resistance to immune checkpoint inhibitors across solid tumors. The company's strategy is built on its UNIFYRs™ platform and proprietary nanoparticle delivery systems, validated by foundational IP and publications in high-impact journals. A key recent partnership with SandboxAQ aims to use AI to accelerate the development of a therapy for glioblastoma, highlighting its deep-tech approach. With a pipeline in early clinical stages, iOncologi is positioning itself at the intersection of RNA biology, immunotherapy, and artificial intelligence.
View full company profileTherapeutic Areas
Other Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| GlioGuard Therapeutic & Diagnostic System | GlioGuard | Pre-clinical |
| DOC1021 | Diakonos Oncology | Phase 2 |
| Lead CAR-T Program | Kiragen Bio | Pre-clinical |
| DCVax®-L | Northwest Biotherapeutics | Phase 3 |
| Lucicebtide (ST101) | Sapience Therapeutics | Phase 2 |
| Glioblastoma Assay Optimization (CPRIT Grant) | SingleCell Biotechnology | Pre-clinical |
| Lead Program (unspecified) | BlueHaven Therapeutics | Preclinical |
| TLX101 (Pixclara® / 131I-IPA) | Telix Pharmaceuticals | Phase 3 |
| Paxalisib | Kazia Therapeutics | Phase II/III |